Objective To investigate the protective effects of etomidate on the cortex and hippocampus against anoxia-reoxygenation (A/R) injury.Methods Male adult SD rats weighing 90-100 g were anesthetized with ether and decapitated. Their brains were immediately removed. Cortical and hippocampal slices were prepared and were randomly divided into 6 groups: group Ⅰ control; groupⅡ A/R; in group Ⅲ - Ⅵ the brain slices were first incubated in the presence of etomidate 3, 6, 15 ?mol?L-1 or etomidate 6 ?mol?L-1 + picrotoxin 50 ?mol?L-1 (GABA receptor antogonist) for 30 min. Then the slices were subjected to 10 min anoxia (95% N2 +5% CO2) followed by 120 min reoxygenation. The absorbance value (A490) of TTC staining (2. 3. 5-triphenyl tetrazolum chloride) and intracellular free Ca2+ ([Ca2+]i) accumulation were determined. Results The A490 in cortical and hippocampal slices were significantly decreased while [Ca2+] i significantly increased in A/R group as compared with control group. Different concentrations of etonlidate attenuated the changes induced by A/R especially 6 ?mol?L-1. The protective effects of etomidate could be antagonized by GABAA antagonist. Conclusion Etomidate can protect the cortex and hippocampus against A/R injury to some extent by acting on GABAA recoptor and decreasing intracellular Ca2+ overloading.

Background and purpose:Huachansu has been widely used to treat cancer in China.But maximum tolerated dose(MTD) of huachansu is still not well defined.The purpose of this study was to conduct a Phase Ⅰ study to determine the MTD of huachansu in the treatment of patients with hepatocellular carcinoma,non-small cell lung or pancreatic cancer.Toxic profile and efficacy of huachansu were also assessed qualitatively.Methods:Huachansu was intravenously administered to patients with stage Ⅲ/Ⅳ hepatocellular carcinoma,non-small cell lung cancer,or pancreatic cancer.Each cycle consisted of daily huachansu for 14 days with an interval of 7 days between two cycles.2 or more cycles were delivered to the patients if no severe adverse event occurred.The planned dose escalation schedule for huachansu was as follows,10,20,40,60,90 and 120 ml/(m2?d).Results:Fifteen patients(3 at each level) have been recruited to the study(11 with hepatocellular carcinoma,2 with pancreatic cancer,and 2 with lung cancer).There were no dose limiting toxicities found after dose level 5.Among all these patients,the efficacy in 14 patients could be valued,in which,6 were SD(42.9%),8 were PD(57.1%).At dose level 1,there was one patient with hepatocellular carcinoma achieving a 20% reduction in tumor mass that lasted 11 months,6 of 15(42.9%) patients with stable disease and 8 of 15(57.1%) with progress disease after the treatment.Conclusions:To date,dose limiting toxicity has not been seen with doses up to eight times higher than that typically used before.Of interest, several patients had prolonged stable disease or minor tumor shrinkage.

Objective:To explore the development, application and practical experience of investigator-initiated integrated clinical research information platform.Methods:The process of developing and constructing an integrated clinical research platform in a tertiary hospital in Beijing was introduced, the functions and advantages of the platform were described and displayed, and the main problems and risk points in the development and construction process were analyzed.Results:The integrated clinical research platform meets the management requirements of clinical research initiated by investigators, and the standardized management of the whole life cycle of the project can be realized through the platform, and the key issues of data security, information capture, sharing and interoperability need to be further explored in terms of platform docking.Conclusions:The integrated clinical research platform effectively improves the standardization, management quality and efficiency of investigator-initiated clinical research.

Primary central nervous system lymphoma (PCNSL) is a rare and special kind of non-Hodgkin lymphoma. Chemotherapy based on high-dose methotrexate (HD-MTX) is considered a standard therapy for newly diagnosed PCNSL, but the prognosis of PCNSL is poor due to its high invasiveness and recurrence rate. Risk stratification and prognosis assessment of PCNSL in diagnosis is particularly important in clinical treatment. At present, MSKCC (the Memorial Sloan Kettering Cancer Center), the International Extranodal Lymphoma Study Group (IELSG) and Nottingham/Barcelona scoring models are mostly used to classify the risk and evaluate the prognosis of PCNSL. With the further understanding of immunohistochemistry and molecular genetics of PCNSL, potential prognostic factors continue to emerge.